Erin H. Seeley

Sep 26, 2024 | nature.com | Sandeep Das |Alexandra C Finney |Sumit Anand |Alia Ghrayeb |Kelley G. Núñez |Fabio Arias | +23 more

AbstractThe incidence of metabolic dysfunction-associated steatohepatitis (MASH) is on the rise, and with limited pharmacological therapy available, identification of new metabolic targets is urgently needed. Oxalate is a terminal metabolite produced from glyoxylate by hepatic lactate dehydrogenase (LDHA). The liver-specific alanine-glyoxylate aminotransferase (AGXT) detoxifies glyoxylate, preventing oxalate accumulation.

Sep 26, 2024 | nature.com | Sandeep Das |Alexandra C Finney |Sumit Anand |Alia Ghrayeb |Kelley G. Núñez |Fabio Arias | +23 more

AbstractThe incidence of metabolic dysfunction-associated steatohepatitis (MASH) is on the rise, and with limited pharmacological therapy available, identification of new metabolic targets is urgently needed. Oxalate is a terminal metabolite produced from glyoxylate by hepatic lactate dehydrogenase (LDHA). The liver-specific alanine-glyoxylate aminotransferase (AGXT) detoxifies glyoxylate, preventing oxalate accumulation.

Feb 15, 2023 | mdpi.com | Edwin Escobar |Jesús E. Serrano-Negrón |David J. Vocadlo |Erin H. Seeley

Abstract: Simple SummaryPost-translational O-glycosylation of proteins with N-acetylglucosamine serves as a cellular regulator that has been linked to cancer. This sugar’s variability is emerging as a metabolic biomarker in cancer, and here we investigate the use of mass spectrometry imaging to visualize the location of this sugar in primary tumor sections.